Table 2.
Model economic parameters and the range of the sensitivity analysis.
| Variables | Base Case (Rang) | Distribution | Source |
|---|---|---|---|
| Costs ($) | |||
| Camrelizumab (200 mg) | 424.35 (339.40-509.10) | Triangle | Local charge |
| Paclitaxel (100 mg) | 108.26 (86.61-129.91) | Triangle | Local charge |
| Cisplatin (100 mg) | 10.97 (8.78-13.16) | Triangle | Local charge |
| Routine follow-up cost per cycle | 73.57 (58.86-88.28) | Triangle | (17) |
| Cost of laboratory tests and radiological examinations | 356.60 (285.28-427.92) | Triangle | (17) |
| Cost of salvage therapy per cycle | 638.43 (510.74-766.12) | Triangle | Local charge |
| Cost of supportive care per cycle | 167.29 (133.83-200.75) | Triangle | (17) |
| Cost of terminal care in end-of-life | 1,460.30 (1,168.24-1,752.36) | Triangle | (18) |
| Costs of serious adverse events ($) | |||
| Anemia | 508.2 (381.2-635.3) | Triangle | (17) |
| White blood cell count decreased | 466.00 (372.80-559.20) | Triangle | (17) |
| Neutrophil count decreased | 534.40 (427.52-641.28) | Triangle | (19) |
| Risks of serious adverse events in CTP group (grade 3 or 4) % | |||
| Anemia | 17.40 (13.92-20.88) | Beta | (11) |
| White blood cell count decreased | 24.20 (19.36-29.04) | Beta | (11) |
| Neutrophil count decreased | 39.90 (31.92-47.88) | Beta | (11) |
| Risks of serious adverse events in PTP group (grade 3 or 4) % | |||
| Anemia | 13.50 (10.80-16.20) | Beta | (11) |
| White blood cell count decreased | 26.60 (21.28-31.92) | Beta | (11) |
| Neutrophil count decreased | 43.40 (34.72-52.08) | Beta | (11) |
| Utility value | |||
| PFS | 0.68 (0.54-0.82) | Beta | (19) |
| PD | 0.42 (0.34-0.50) | Beta | (19) |
| Body surface area (m2) | 1.72 (1.38-2.06) | Triangle | (17) |
| Discount rate (%) | 3 (0–8) | Fixed in PSA | (13) |
CTP, camrelizumab-chemotherapy; PTP, placebo-chemotherapy; PFS, progression-free survival; PD, progressive disease; PSA, probabilistic sensitivity analyses.